Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations

Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation due to unknown causes. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and tofacitinib, a targeted sDMARD, can be used to treat RA. In clinical trials, molecular-targeted...

Descripción completa

Detalles Bibliográficos
Autor principal: Koike, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Instructional Lecture
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653232/
https://www.ncbi.nlm.nih.gov/pubmed/26404390
http://dx.doi.org/10.1007/s00776-015-0766-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653232/
https://www.ncbi.nlm.nih.gov/pubmed/26404390
http://dx.doi.org/10.1007/s00776-015-0766-9

Ejemplares similares